Paper Details

  1. Home
  2. Paper Details

Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.

Author: CiaranelloAndrea L, ClementMeredith E, CohenMyron S, FreedbergKenneth A, GrinsztejnBeatriz, HyleEmily P, LandovitzRaphael J, LeMylinh H, McCauleyMarybeth, NeilanAnne M, PaltielA David, ReddyKrishna P, WalenskyRochelle P, WattananimitgulNattanicha

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Long-acting injectable cabotegravir (CAB-LA) for HIV preexposure prophylaxis (PrEP) could achieve an incremental cost-effectiveness ratio (ICER) of at most $100,000 per quality-adjusted life-year (QALY) compared with generic emtricitabine-tenofovir disoproxil fumarate (F/TDF).
Paper Details　
Original Abstract of the Article :
BACKGROUND: The HIV Prevention Trials Network (HPTN) 083 trial demonstrated the superiority of long-acting injectable cabotegravir (CAB-LA) compared with oral emtricitabine-tenofovir disoproxil fumarate (F/TDF) for HIV preexposure prophylaxis (PrEP). OBJECTIVE: To identify the maximum price premium...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/35099992

データ提供：米国国立医学図書館（NLM）

Long-Acting Injectable HIV Preexposure Prophylaxis: Finding the Right Oasis in the Desert of HIV Prevention

HIV preexposure prophylaxis (PrEP) is a highly effective way to prevent HIV infection. This cost-effectiveness analysis explores the potential value of long-acting injectable cabotegravir (CAB-LA) compared to oral PrEP options. Imagine a desert landscape where researchers seek the most effective and cost-efficient approach to protecting against HIV. The researchers used a simulation model to estimate the cost-effectiveness of CAB-LA compared to oral PrEP options, considering factors such as drug costs, HIV incidence rates, and PrEP retention rates. The findings suggest that CAB-LA could be a cost-effective option for PrEP, especially among individuals at very high risk of HIV infection. However, the researchers also highlight the need for careful consideration of price premiums and the potential for cost-effectiveness to vary depending on the specific population and risk factors.

The Potential of Long-Acting Injectable PrEP

This cost-effectiveness analysis suggests that CAB-LA could be a valuable addition to the PrEP toolkit, offering a potentially cost-effective and convenient option for high-risk individuals. It's like finding a new and efficient oasis in the desert of HIV prevention. Further research is needed to refine the cost-effectiveness estimates and to explore the broader impact of CAB-LA on HIV prevention efforts.

Preventing HIV: A Camel's Advice

If you are at risk of HIV infection, it's important to talk to your healthcare provider about PrEP options. It's like preparing for a journey across a vast and unpredictable desert. PrEP can provide a valuable layer of protection against HIV, reducing your risk of infection. It's important to discuss your individual needs and preferences with your healthcare provider to determine the best approach for you.

Dr.Camel's Conclusion

This cost-effectiveness analysis provides valuable insights into the potential of CAB-LA as a cost-effective PrEP option for high-risk individuals. It's a reminder that even in the vast and challenging desert of HIV prevention, we are constantly seeking innovative solutions to protect global health.

Date :
  1. Date Completed 2022-04-20
  2. Date Revised 2023-04-02
Further Info :

Pubmed ID

35099992

DOI: Digital Object Identifier

NIHMS1776366

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.